Transient Ischemic Attack (TIA)
Table of Contents
- What a Transient Ischemic Attack Is
- Transient Ischemic Attack vs Stroke: Key Differences
- FAST Warning Signs
- ABCD2 Score — Predicting Stroke Risk
- Risk Factors
- Urgent Diagnosis
- Same-Day Transient Ischemic Attack Clinic — The EXPRESS Trial
- Acute Management
- Secondary Prevention
- Lifestyle and Natural Approaches
- Key Research Papers
- Connections
- Featured Videos
What a Transient Ischemic Attack Is
A transient ischemic attack (TIA) — commonly called a "mini-stroke" — is a brief episode of neurological dysfunction caused by temporary loss of blood flow to a part of the brain, spinal cord, or retina, without causing permanent infarction. Symptoms resolve completely, usually within minutes to an hour, and virtually always within 24 hours.
The term "mini-stroke" is dangerously misleading because it implies transient ischemic attack is minor. In reality, a transient ischemic attack is a medical emergency. Within 48 hours of a transient ischemic attack, roughly 5% of patients will have a full stroke — and within 90 days, 10–15% will have a disabling or fatal stroke. Urgent evaluation and treatment can reduce that 90-day risk by more than 80%.
Approximately 240,000 TIAs are diagnosed annually in the United States, though the true number is likely higher because many patients dismiss mild or fleeting symptoms and do not seek care.
Transient Ischemic Attack vs Stroke: Key Differences
The distinction between transient ischemic attack and ischemic stroke was historically based on duration — symptoms lasting less than 24 hours were called transient ischemic attack. The modern tissue-based definition is more precise:
- Transient ischemic attack (tissue-based definition): Transient neurological symptoms with no infarction on brain imaging (DWI-MRI negative or shows no new lesion). Symptoms typically resolve within 1 hour in most true TIAs.
- Minor ischemic stroke: Symptoms resolve, but DWI shows a small area of permanent infarction. NIHSS score ≤3–5. Often treated identically to transient ischemic attack in the acute phase.
- Ischemic stroke: Persistent neurological deficit with infarction on imaging.
Clinically, this distinction matters because up to 40% of events meeting the old "symptoms resolved within 24 hours" definition actually show infarction on magnetic resonance imaging (MRI) — meaning they were minor strokes, not true TIAs. These patients have higher early recurrence risk than pure TIAs without imaging evidence of infarction.
FAST Warning Signs
Transient ischemic attack produces the same warning signs as stroke — the critical difference is that they resolve. hospitals treat these signs as an emergency even when they fade, because a transient ischemic attack cannot be told apart from a stroke in the first minutes — emergency services (911 in the U.S.) are called without waiting to see if symptoms go away:
- F — Face drooping: One side of the face droops or feels numb. Uneven smile.
- A — Arm weakness: One arm is weak, numb, or drifts downward when both are raised.
- S — Speech difficulty: Slurred, garbled, wrong-word substitutions, or inability to speak or understand others.
- T — Time to call 911: Even if symptoms resolve during the 911 call, an immediate emergency department visit is still the standard response.
Additional transient ischemic attack symptoms include sudden monocular vision loss (amaurosis fugax — like a shade being pulled over one eye), sudden loss of sensation on one side, sudden severe dizziness or loss of balance, and sudden confusion or memory gap.
Amaurosis fugax (temporary blindness in one eye) is a classic transient ischemic attack variant from retinal artery embolism originating in the ipsilateral carotid artery. It resolves within minutes and strongly predicts carotid artery disease.
ABCD2 Score — Predicting Stroke Risk After Transient Ischemic Attack
The ABCD2 score is a validated clinical tool that estimates the 2-day and 7-day risk of stroke after a transient ischemic attack. It helps triage urgency of workup and treatment:
- A — Age ≥60 years: 1 point
- B — Blood pressure ≥140/90 mmHg at presentation: 1 point
- C — Clinical features:
- Unilateral weakness: 2 points
- Speech disturbance without weakness: 1 point
- Other symptoms: 0 points
- D — Duration of symptoms:
- ≥60 minutes: 2 points
- 10–59 minutes: 1 point
- <10 minutes: 0 points
- D — Diabetes: 1 point
Total score interpretation:
- 0–3 (low): 1.0% 2-day stroke risk
- 4–5 (moderate): 4.1% 2-day stroke risk
- 6–7 (high): 8.1% 2-day stroke risk
Important caveat: The ABCD2 score has limitations and is not used to delay workup or defer hospital admission in patients with first transient ischemic attack. Current guidelines recommend urgent evaluation (ideally same-day) for all transient ischemic attack patients regardless of ABCD2 score.
Risk Factors
- Hypertension: Present in 60–70% of transient ischemic attack patients. Systolic blood pressure (BP) above 140 mmHg is the strongest modifiable risk factor for transient ischemic attack and subsequent stroke.
- Atrial fibrillation: Causes cardioembolic transient ischemic attack through clot formation in the left atrial appendage. May be paroxysmal and go undetected on standard electrocardiogram (ECG) — detection needs prolonged monitoring.
- Carotid artery stenosis: Atherosclerotic plaque in the ipsilateral internal carotid artery causes artery-to-artery embolism to the hemispheric or retinal arteries.
- Diabetes: Doubles risk through accelerated atherogenesis and hypercoagulability.
- Smoking: Doubles transient ischemic attack and stroke risk; synergizes with oral contraceptive use in young women.
- Dyslipidemia: Elevated low-density lipoprotein (LDL) accelerates carotid and intracranial atherosclerosis.
- Patent foramen ovale (PFO): In young patients with cryptogenic transient ischemic attack/stroke, PFO allows paradoxical embolism of venous thrombi into the arterial circulation. PFO closure is beneficial in selected young patients (CLOSE, REDUCE trials).
- Prior transient ischemic attack: One transient ischemic attack markedly increases the risk of future transient ischemic attack and stroke — making secondary prevention urgent after the very first event.
Urgent Diagnosis
Transient ischemic attack workup is completed urgently — ideally within 24 hours — because the highest risk of stroke is in the first 48 hours. Delays allow preventable strokes to occur.
- Brain magnetic resonance imaging with DWI: The definitive test to determine whether infarction occurred. Superior to computed tomography (CT) for detecting small or posterior fossa lesions. Ideally performed within 24 hours of symptom onset.
- CT/CTA: Rapid non-contrast computed tomography to exclude hemorrhage; CTA to evaluate carotid and intracranial arteries for stenosis or occlusion. Available around the clock in most emergency departments.
- Carotid imaging: Carotid ultrasound, CTA, or MRA to detect ipsilateral stenosis. Symptomatic carotid stenosis ≥50% changes management (endarterectomy or stenting).
- 12-lead electrocardiogram: Immediate — looking for atrial fibrillation, flutter, or recent myocardial infarction.
- Prolonged cardiac monitoring: Holter monitor (24–48 hours), 30-day external monitoring, or an insertable cardiac monitor (implanted under the skin for months to years) detects paroxysmal atrial fibrillation (AF) in 10–20% of cryptogenic transient ischemic attack/stroke patients. In the CRYSTAL-AF trial of patients with cryptogenic stroke, an insertable cardiac monitor detected atrial fibrillation in 8.9% of patients by 6 months versus 1.4% with conventional follow-up (12.4% vs 2.0% by 12 months).
- Laboratory workup: Complete blood count (polycythemia, thrombocytosis), coagulation studies, fasting lipid panel, hemoglobin A1c (HbA1c), and in young patients: hypercoagulable states (antiphospholipid syndrome, factor V Leiden, protein C/S deficiency).
- Echocardiography: Transthoracic echo for structural heart disease; transesophageal echo superior for detecting PFO, left atrial appendage thrombus, and aortic arch atheroma.
Same-Day Transient Ischemic Attack Clinic — The EXPRESS Trial
The EXPRESS trial (Early use of eXisting PREventive Strategies for Stroke, published 2007) is one of the most important pragmatic trials in stroke medicine. It demonstrated that organizing care around a same-day transient ischemic attack clinic with immediate initiation of preventive treatment — rather than the traditional "wait for outpatient neurology" approach — dramatically reduces early stroke risk.
In the trial, patients who received same-day evaluation and started treatment immediately had a 90-day stroke risk of 2.1% versus 10.3% in the control period — an 80% relative risk reduction. This represents one of the largest absolute risk reductions ever achieved in preventive neurology.
Key elements of the EXPRESS approach:
- Immediate aspirin (or dual antiplatelet) on presentation
- Same-day imaging (brain magnetic resonance imaging and vascular imaging)
- Same-day specialist review
- Immediate initiation of antihypertensive therapy if blood pressure is elevated
- Early statin initiation
This trial changed guidelines worldwide. Current American Heart Association/American Stroke Association guidelines recommend that all transient ischemic attack patients be evaluated urgently, with high-ABCD2 patients seen within 24 hours and ideally admitted for expedited workup.
Acute Management
Unlike ischemic stroke, tPA is generally not indicated for transient ischemic attack because symptoms have resolved and there is no demonstrated ischemic tissue to salvage. However, acute management is still urgent:
- Antiplatelet therapy: An aspirin loading dose of 300–325 mg is given immediately once hemorrhage is excluded on imaging, then continued at 75–100 mg daily.
- Dual antiplatelet therapy (DAPT): For minor stroke or high-risk transient ischemic attack (ABCD2 ≥4), aspirin plus clopidogrel for 21 days (CHANCE trial) or up to 90 days (POINT trial) reduces early recurrence by approximately 25–30% compared to aspirin alone. After this period, monotherapy is preferred to reduce bleeding risk.
- Blood pressure management: Aggressive acute lowering in the first 24 hours is generally not used (it may reduce perfusion in borderline ischemic territory). After 24 hours, antihypertensive therapy is started or intensified toward a target below 130/80 mmHg.
- Carotid endarterectomy (CEA): For symptomatic carotid stenosis ≥50–70%, CEA performed within 2 weeks of the transient ischemic attack provides maximum benefit. Delaying surgery beyond 2 weeks loses most of the protective effect.
- Anticoagulation for atrial fibrillation: If atrial fibrillation is identified, a direct oral anticoagulant (DOAC; preferred over warfarin) is started as soon as it is safe — often within 2–7 days after minor transient ischemic attack, balancing hemorrhagic transformation risk against recurrent cardioembolic events.
Secondary Prevention
Long-term prevention after transient ischemic attack mirrors stroke secondary prevention:
- Antiplatelet therapy (non-cardioembolic): Aspirin monotherapy 75–100 mg daily remains standard after the initial DAPT window. Clopidogrel 75 mg daily is an alternative for aspirin-intolerant patients; in the CAPRIE trial it had an annual 5.32% risk of ischemic stroke, myocardial infarction, or vascular death versus 5.83% with aspirin (an 8.7% relative risk reduction).
- Anticoagulation (cardioembolic/atrial fibrillation): DOAC (apixaban, rivaroxaban, dabigatran) long-term for atrial fibrillation-related transient ischemic attack. International normalized ratio-targeted warfarin if DOAC is contraindicated.
- High-intensity statin: Atorvastatin 80 mg or rosuvastatin 40 mg regardless of baseline low-density lipoprotein. Reduces recurrent events by 16–25%.
- Blood pressure control: Target systolic below 130 mmHg. Angiotensin-converting enzyme inhibitors (especially perindopril) and thiazide diuretics have the strongest evidence in secondary stroke/transient ischemic attack prevention (PROGRESS trial).
- Glucose control in diabetics: hemoglobin A1c target below 7%; avoids hypoglycemia (which can trigger neurological symptoms mimicking transient ischemic attack).
- PFO closure: In patients under 60 with cryptogenic transient ischemic attack/minor stroke and a large or moderate PFO with atrial septal aneurysm, device closure reduces recurrence compared to antiplatelet therapy alone (CLOSE trial).
Lifestyle and Natural Approaches
Transient ischemic attack is a powerful warning signal — the research links the lifestyle factors below to future stroke risk:
- Mediterranean diet: Reduces vascular events by 30% in the PREDIMED trial. Provides anti-inflammatory polyphenols, omega-3 fatty acids, and potassium — all beneficial for endothelial function and blood pressure.
- Regular aerobic exercise: 150 minutes per week of moderate activity reduces blood pressure, improves lipid profile, reduces atrial fibrillation burden, and lowers body weight. All translate directly to reduced stroke risk.
- Smoking cessation: Single most impactful modifiable risk factor in many patients. Risk returns to near-baseline within 5 years. Combination pharmacotherapy (varenicline + nicotine replacement therapy, NRT) is associated with the best quit rates.
- Alcohol reduction: U.S. dietary guidance sets the limit at ≤1 drink/day for women and ≤2/day for men. Heavier drinking causes hypertension, atrial fibrillation, and thrombocytopenia — all stroke risk factors.
- Weight management: Even modest 5–10% weight loss significantly reduces blood pressure, improves insulin sensitivity, and reduces atrial fibrillation burden in overweight individuals.
- Omega-3 fatty acids: eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) from fatty fish or supplements reduce triglycerides and cardiovascular risk. The REDUCE-IT trial tested icosapent ethyl (a highly purified EPA ethyl ester, 2 g twice daily) in statin-treated patients with fasting triglycerides of 135–499 mg/dL and found fewer ischemic events than with placebo.
- DASH diet: Dietary Approaches to Stop Hypertension reduces systolic blood pressure by 8–14 mmHg — comparable to a single antihypertensive medication. High in potassium, calcium, magnesium, and low in sodium.
Key Research Papers
Pivotal trials that define modern transient ischemic attack management:
- Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007;370(9596):1432–1442. — PubMed PMID: 17928046
- Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369(9558):283–292. — PubMed PMID: 17258668
- Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE). N Engl J Med. 2013;369(1):11–19. — PubMed PMID: 23803136
- Johnston SC et al., 2018 — POINT Trial: Clopidogrel + aspirin vs aspirin after TIA/minor stroke. — PubMed PMID: 29766750
- Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236. — PubMed PMID: 24788967
- Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation (CRYSTAL AF). N Engl J Med. 2014;370(26):2478–2486. — PubMed PMID: 24963567
- Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke (CLOSE). N Engl J Med. 2017;377(11):1011–1021. — PubMed PMID: 28902593
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–1339. — PubMed PMID: 8918275
- PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–1041. — PubMed PMID: 11589932
- Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack (SPARCL). N Engl J Med. 2006;355(6):549–559. — PubMed PMID: 16899775
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11–22. — PubMed PMID: 30415628